Clinical Trial Update: Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance in multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Empliciti (elotuzumab)
• Revlimid (lenalidomide)

Snippet

Sponsor: Hearn Jay Cho | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED